ClinicalTrials.Veeva

Menu
V

Victoria Clinical Research Group | Victoria, TX

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

LY3502970
Dulaglutide
Orforglipron
Rimegepant

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

4 of 6 total trials

A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults

The main objective of Part A of this trial is to evaluate the safety and reactogenicity of mRNA-1189 in 18- to 30-year-old healthy adults, the main o...

Active, not recruiting
Epstein-Barr Virus Infection
Biological: mRNA-1189
Biological: Placebo

This study looks at how well a medicine called orforglipron works compared to another medicine called dulaglutide in pediatric participants aged 10 t...

Begins enrollment in 1 month
Diabetes Mellitus, Type 2
Drug: Orforglipron
Drug: Dulaglutide

The purpose of this study is to compare the efficacy and safety of rimegepant to placebo as a preventative treatment for migraine in children and ado...

Enrolling
Migraine
Drug: Placebo
Drug: Rimegepant

The purpose of this study is to learn about the safety of a new pneumococcal vaccine and how the new pneumococcal vaccine helps to fight against germ...

Enrolling
Pneumococcal Disease
Biological: PG4
Biological: 20-valent pneumococcal conjugate vaccine (20vPnC)

Trial sponsors

Moderna logo
Pfizer logo
Lilly logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems